bivalent mrna-1273
Trade name: Spikevax bivalent
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05543356)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05543356 | Phase 3 | Feb 28, 2023 | Coalition for Epidemic Preparedness Innovations, Murdoch University, The Peter Doherty Institute |
| NCT05658523 | Phase 3 | Feb 28, 2023 | Coalition for Epidemic Preparedness Innovations, Murdoch University, The Peter Doherty Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Murdoch University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| The Peter Doherty Institute | Academic/Hospital | 2 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1